This now returns us to the third possible explanation of the adverse outcome with torcetrapib in ILLUMINATE (Figure): the possibility that torcetrapib had an adverse off-target effect pharmacologically unrelated to CETP inhibition.
J Clin Lipidol. 2011; 5(6).